Kai-Can Cai Selected Research

Therapeutics

1/2020

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kai-Can Cai Research Topics

Disease

2	Coronary Artery Disease (Coronary Atherosclerosis) 05/2002 - 01/2002
1	Esophageal Squamous Cell Carcinoma 01/2021
1	Neoplasms (Cancer) 01/2021
1	Adenocarcinoma of Lung 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2017
1	Aortic Dissection 01/2017
1	Hemorrhage 01/2017
1	Neurologic Manifestations (Neurological Manifestations) 01/2017
1	Paraplegia (Spastic Paraplegia) 01/2017
1	Pulmonary Atelectasis 10/2015
1	Diaphragmatic Hernia 10/2015
1	Lung Diseases (Lung Disease) 10/2015
1	Esophageal Diseases 10/2015
1	Mitral Valve Insufficiency (Mitral Regurgitation) 05/2002

Drug/Important Bio-Agent (IBA)

1	N-methyladenosineIBA 01/2021
1	6-methyladenineIBA 01/2021
1	PlatinumIBA 01/2020
1	Pemetrexed (MTA)FDA Link 01/2020

Therapy/Procedure

2	Cardiopulmonary Bypass (Heart-Lung Bypass) 05/2002 - 01/2002
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 05/2002 - 01/2002
1	Therapeutics 01/2020
1	Drug Therapy (Chemotherapy) 01/2020
1	Extracorporeal Circulation 01/2017
1	Renal Dialysis (Hemodialysis) 01/2017
1	Chest Tubes (Chest Tube) 01/2017
1	Stents 01/2017
1	Length of Stay 10/2015